242 related articles for article (PubMed ID: 21471134)
1. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
Banegas JR; López-García E; Dallongeville J; Guallar E; Halcox JP; Borghi C; Massó-González EL; Jiménez FJ; Perk J; Steg PG; De Backer G; Rodríguez-Artalejo F
Eur Heart J; 2011 Sep; 32(17):2143-52. PubMed ID: 21471134
[TBL] [Abstract][Full Text] [Related]
2. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
[TBL] [Abstract][Full Text] [Related]
3. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.
Kotseva K; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Abreu A; Aguiar C; Conde AC; Davletov K; Dilic M; Dolzhenko M; Gaita D; Georgiev B; Gotcheva N; Lalic N; Laucevicius A; Lovic D; Mancas S; Miličić D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Vulic D; Wood D; On Behalf Of The Euroaspire Investigators
Eur J Prev Cardiol; 2016 Dec; 23(18):2007-2018. PubMed ID: 27638542
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of cardiovascular disease in Greece: Greek results of the EURIKA study.
Elisaf M; Tzouvelekis E; Nikas N;
Hellenic J Cardiol; 2014; 55(3):217-26. PubMed ID: 24862614
[TBL] [Abstract][Full Text] [Related]
5. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
8. Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.
Figliuzzi I; Presta V; Citoni B; Miceli F; Simonelli F; Battistoni A; Coluccia R; Ferrucci A; Volpe M; Tocci G
Clin Cardiol; 2018 Jun; 41(6):788-796. PubMed ID: 29604091
[TBL] [Abstract][Full Text] [Related]
9. Primary Prevention of Cardiovascular Risk in Lithuania-Results from EUROASPIRE V Survey.
Urbonas G; Vencevičienė L; Valius L; Krivickienė I; Petrauskas L; Lazarenkienė G; Karpavičienė J; Briedė G; Žučenkienė E; Vencevičius K
Medicina (Kaunas); 2020 Mar; 56(3):. PubMed ID: 32197516
[No Abstract] [Full Text] [Related]
10. Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.
Guallar E; Banegas JR; Blasco-Colmenares E; Jiménez FJ; Dallongeville J; Halcox JP; Borghi C; Massó-González EL; Tafalla M; Perk J; De Backer G; Steg PG; Rodríguez-Artalejo F
BMC Public Health; 2011 Sep; 11():704. PubMed ID: 21923932
[TBL] [Abstract][Full Text] [Related]
11. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP.
Wens J; Gerard R; Vandenberghe H
Prim Care Diabetes; 2011 Apr; 5(1):19-24. PubMed ID: 21030327
[TBL] [Abstract][Full Text] [Related]
12. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study.
Banegas JR; López-García E; Dallongeville J; Guallar E; Halcox JP; Borghi C; Massó-González EL; Sazova O; Perk J; Steg PG; De Backer G; Rodríguez-Artalejo F
Int J Cardiol; 2013 Jun; 166(1):210-4. PubMed ID: 22056474
[TBL] [Abstract][Full Text] [Related]
13. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).
Rodríguez-Artalejo F; Guallar E; Borghi C; Dallongeville J; De Backer G; Halcox JP; Hernández-Vecino R; Jiménez FJ; Massó-González EL; Perk J; Steg PG; Banegas JR;
BMC Public Health; 2010 Jun; 10():382. PubMed ID: 20591142
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
Vrablík M; Chmelík Z; Lánská V
Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors among high-risk individuals attending the general practice at king Abdulaziz University hospital: a cross-sectional study.
Ghamri RA; Alzahrani NS; Alharthi AM; Gadah HJ; Badoghaish BG; Alzahrani AA
BMC Cardiovasc Disord; 2019 Nov; 19(1):268. PubMed ID: 31775642
[TBL] [Abstract][Full Text] [Related]
16. Management of cardiovascular risk factors for primary prevention: evaluation of Turkey results of the EURIKA study.
Abaci A
Turk Kardiyol Dern Ars; 2012 Mar; 40(2):135-42. PubMed ID: 22710584
[TBL] [Abstract][Full Text] [Related]
17. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
[TBL] [Abstract][Full Text] [Related]
18. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
[TBL] [Abstract][Full Text] [Related]
20. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
